Digital therapeutics (DTx) startup Dopavision has raised funding to develop its lead product, an app designed to slow the progression of myopia – or short-sightedness – in children or adole
Digital startup Dopavision has raised cash in a seed funding round backed by Boehringer Ingelheim, to develop a smartphone-based digital therapy for myopia (short-sightedness).
Novo Nordisk has partnered with Ascendis Pharma on less frequently dosed drugs for obesity and other metabolic diseases, starting with a once-monthly GLP-1 receptor agonist.
